Adverse events associated with BNT162b2 vaccination ID’d
Aug 27, 2021
Vaccination with the Pfizer–BioNTech mRNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with an increased risk for myocarditis and lymphadenopathy, according...
Protection against SARS-CoV-2 wanes months after BNT162b2 vaccination
Oct 08, 2021
Declines were seen in humoral responses and effectiveness against SARS-CoV-2 infection within several months after the second dose of the Pfizer-BioNTech vaccine, also known as Comirnaty.
Vaccines effective in preventing symptomatic COVID-19 in healthcare workers
Sep 27, 2021
Effectiveness was similar regardless of age (
COVID-19 vaccination tied to decline in distress in U.S. adults
Feb 24, 2022
Decreases in distress and perceived risks for infection, hospitalization and death were reported by those receiving at least one dose of the vaccine.
SARS-CoV-2 vaccines effectively prevent infection in VA population
Jul 20, 2021
Vaccine effectiveness was 96.2% for Pfizer-BioNTech BNT162b2 and 98.2% for Moderna mRNA-1273.
Statin use not linked to COVID-19 mortality in hospitalized patients
Nov 09, 2021
Statin use was associated with an increased relative risk for severe disease among hospitalized patients with COVID-19.
mRNA COVID-19 vaccine less protective in elderly with comorbidity
Dec 23, 2021
At ≥7 days after the second dose, the effectiveness of mRNA COVID-19 vaccine was 69% against infection and 86% against related death.
Most with reaction to mRNA COVID-19 vaccine tolerate second dose
Jul 29, 2021
Most patients with an immediate, potentially allergic reaction to Pfizer-BioNTech or Moderna mRNA COVID-19 vaccine tolerate a second dose
COVID-19 vaccine hesitancy up for racial, ethnic minority healthcare workers
Aug 30, 2021
Vaccine hesitancy was highest among Black and Hispanic or Latino healthcare workers; concerns include side effects and the newness of the vaccine.
Veterans report low rates of adverse events with mRNA vaccines
Jun 16, 2022
Rates were slightly higher at 42 days for those receiving the Pfizer versus Moderna vaccine.